A Phase 3 interventional study of Denecimig in Haemophilia A, sponsored by Novo Nordisk A/S. Recruiting at 83 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 14th largest by planned enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2026, is one of 21 in phase 3, reaches primary completion later than 9 of the 11 other live ones, and was the 92nd registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Austria, Belgium and 9 more countries
Ages 18–64 · Men only · Healthy volunteers
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 12+
Novo Nordisk A/S · Sites in India, Malaysia, Korea, Republic of and 1 more country
Novo Nordisk A/S · Sites in Japan
By country, each count listing its studies:
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 84 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 38 across the 59 interventional studies, 86 across the 32 observational. Of the 78 that completed or were terminated, 20 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
4 of the studies in Hemophilia A by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04682145Novo Nordisk A/SAdverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol | 2026-12-01 |
| NCT07653139Novo Nordisk A/SPatient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany | 2026-12-26 |
| NCT07220564Novo Nordisk A/SA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A | 2027-02-05 |
| NCT04574076Novo Nordisk A/SA Study Following Males With Haemophilia A on Prophylaxis With Esperoct® | 2027-06-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out if denecimig is safe and effective for treating people who have acquired haemophilia A. Participants will be in this study for up to around 1 year and 5 months (73 week).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Denecimig will be administered subcutaneously.
Drug: Denecimig
Participants will receive subcutaneous (s.c.) injections of denecimig.
Number of treated bleeds
Measured as count of treated bleeds.
Time frame: From treatment initiation (week 0) until end of main part (week 12)
Number of treated bleeds
Measured as count of treated bleeds.
Time frame: From initiation of extension part (week 13) up until end of treatment (week 52)
Number of clinically relevant new bleeds
Measured as count of new bleeds.
Time frame: From treatment initiation (week 0) up until end of treatment (week 52)
Days of treatment with bypassing agent (BPAs) or coagulation factor VIII (FVIII) products for management of bleeding episodes
Measured as count of bleeds.
Time frame: From treatment initiation (week 0) up until end of treatment (week 52)
Occurrence of infections
Measured as count of infections.
Time frame: From treatment initiation (week 0) up until end of study (week 73)
Occurrence of antidrug antibodies
Measured as count of antidrug antibodies.
Time frame: From treatment initiation (week 0) up until end of study (week 73)
Denecimig plasma concentration
Measured as microgram per milliliter (μg/mL).
Time frame: From treatment initiation (week 0) up until end of treatment (week 52)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Mar 2029, 29 months after the start.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 29 months is close to that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denecimig